Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

We recently published a list of 10 Stocks Skyrocketing Today. In this article, we are going to take a look at where Viking ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...

Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...

In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $29.10, with a +1.46% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily gain ...

In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $29.10, with a +1.46% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0 ...

After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...